In a decisive move on March 31, 2026, Benchmark’s Bruce D. Jackson upgraded Humacyte, Inc. (HUMA) to a speculative buy rating. This rating comes with a price target set at $1, which aligns closely with HUMA’s recent trading price of $0.6067. For investors, this development suggests that, despite the company’s tumultuous performance over the past year, there may be potential upside worth considering.
Recent Price Action
Humacyte’s stock has seen significant volatility recently, with its price settling at $0.6067 after a change of $0.0322, equating to a 5.6% increase on the day. This uptick occurs against a backdrop of stark 52-week fluctuations, with a high of $39.77 and a low reaching $0.39. The trading volume for recent sessions has reflected a bustling market, with approximately 7,059,128 shares changing hands compared to an average volume of 6,413,333. With a market capitalization hovering around $95 million and a beta of 1.928, HUMA exhibits a higher volatility compared to the broader market, indicating that price swings may be expected as investors react to both company announcements and broader economic signals.
[chart type=’price’ value=’HUMA’]
Short- and Long-Term Performance
Over the past 30 days, HUMA has posted a decline of approximately 4.67%, while its quarterly performance has plummeted by 40.7%. The one-year performance tells a more sobering story with an overall drop of 77.23%. This considerable depreciation highlights the challenges that Humacyte has faced in the market, raising questions about management and future prospects. The stock’s volatility stands at 6.94% weekly and 7.59% monthly, indicating inconsistent investor sentiment and reaction to fluctuating market conditions. Despite these hurdles, the ten-day average volume suggests a budding interest, as trading patterns indicate a shift of 10,946,485 shares—a notable spike over three-month averages.
[chart type=’performance’ value=’HUMA’]
Earnings / Financials
Humacyte’s latest earnings report presents a mixed bag, with an earnings per share (EPS) of -$0.11 that exceeded the estimated EPS of -$0.17 by 35%. This positive surprise signals some financial resilience, particularly given the company’s previous report, where the actual EPS of -$0.24 fell short of a projected -$0.15, marking a disappointing 60% negative surprise. Investors may find the latest results encouraging, suggesting that operational improvements might be underway or that expenses could be coming under control, despite the overall losses.
[chart type=’income-bar-chart’ value=’HUMA’]
Analyst / Consensus View
The market sentiment surrounding HUMA is dominated by a consensus of 13 ratings, with 12 classified as “Buy,” one as “Hold,” and none as “Sell.” This overwhelmingly bullish stance is reinforced by an average price target of $15.15, suggesting substantial potential upside compared to the current trading price. The projected price target varies widely, from a low of $1 to a high of $25, indicating varying levels of confidence among analysts regarding Humacyte’s path forward. The speculative buy rating from Benchmark marks a pivotal moment and could lead to increased interest among investors weighing risk against potential reward.
[chart type=’analyst-ratings’ value=’HUMA’]
Stock Grading or Fundamental View
The Stocks Telegraph Grading Score for Humacyte stands at a concerning 30, reflecting the company’s significant hurdles in terms of financial health and market performance. This low score indicates that the fundamentals may not fully support a robust investment thesis at this time. Investors should approach the stock with caution, keeping in mind the inherent risks and volatility characterizing its recent performance trajectory.
[chart type=’st-cards’ value=’HUMA’]
Conclusion
Humacyte, Inc. may attract interest from speculative and risk-tolerant investors following the upgrade to a speculative buy rating. While the potential for significant upside exists, particularly given analysts’ generous price targets, the company’s substantial year-over-year decline reveals deeper structural challenges that cannot be overlooked. Investors looking for long-term growth may want to exercise caution, weighing the risks of further decline against the potential for recovery. As markets fluctuate, keeping a close eye on HUMA’s forthcoming financial results and operational updates will be essential for gauging the effectiveness of its recovery strategies.